Dernière mise à jour : 05 décembre 2013
Détails
FichiersGeneric Name:
Pemetrexed
État du projet:
Terminé
Fabricant:
Eli Lilly Canada
Brand Name:
Alimta
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0027-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
100mg/vial and 500mg/vial
Tumour Type:
Lung
Indications:
Advanced Non-Squamous Non Small Cell Lung Cancer
Funding Request:
For maintenance following first-line pemetrexed and cisplatin for advanced or metastatic Non Squamous -Non Small Cell Lung Cancer (NS-NSCLC)
Review Status:
Complete
Sponsor:
Eli Lilly Canada
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 05 décembre 2013